Paper41136631
Bispecific antibodies (PD-1/CTLA-4) vs. PD-1 inhibitors with platinum-based chemotherapy±bevacizumab as first-line therapy for persistent, recurrent, or metastatic cervical cancer: a retrospective matched cohort study.
Wang X and 4 others. Cancer Immunol Immunother, 2025. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Bispecific antibodies (PD-1/CTLA-4) vs. PD-1 inhibitors with platinum-based chemotherapy±bevacizumab as first-line therapy for persistent, recurrent, or metastatic cervical cancer: a retrospective matched cohort study. Papers, record 41136631. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41136631
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Bispecific antibodies (PD-1/CTLA-4) vs. PD-1 inhibitors with platinum-based chemotherapy±bevacizumab as first-line therapy for persistent, recurrent, or metastatic cervical cancer: a retrospective matched cohort study.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Uterine Cervical Neoplasms | Major topic |
| Neoplasm Recurrence, Local | Major topic |
| Immune Checkpoint Inhibitors | Major topic |
| Programmed Cell Death 1 Receptor | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Antibodies, Bispecific | Major topic |
| Humans | |
| Female | |
| Retrospective Studies | |
| Middle Aged | |
| Bevacizumab | |
| Aged | |
| Adult | |
| CTLA-4 Antigen | |
| Prognosis |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 82172804 | National Natural Science Foundation of China | PubMed |
Source PubMed
References21
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38048793 | Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial. | Lancet | 2024 | https://conductscience.org/library/papers/38048793 | PubMed |
| 2 | 35636017 | ROS generation attenuates the anti-cancer effect of CPX on cervical cancer cells by inducing autophagy and inhibiting glycophagy. | Redox Biol | 2022 | https://conductscience.org/library/papers/35636017 | PubMed |
| 3 | 39843940 | First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. | Nat Med | 2025 | https://conductscience.org/library/papers/39843940 | PubMed |
| 4 | 33661538 | Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer. | Cochrane Database Syst Rev | 2021 | https://conductscience.org/library/papers/33661538 | PubMed |
| 5 | 36793374 | Effect of Exosomal lncRNA MALAT1/miR-370-3p/STAT3 Positive Feedback Loop on PI3K/Akt Pathway Mediating Cisplatin Resistance in Cervical Cancer Cells. | J Oncol | 2023 | https://conductscience.org/library/papers/36793374 | PubMed |
| 6 | 39905663 | Efficacy and Safety of Anlotinib and PD-1/L1 Inhibitors as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Patients who Have Achieved Stable-Disease After First-Line Treatment with Chemotherapy and Immunotherapy: A Retrospective Study. | Cancer Control | 2025 | https://conductscience.org/library/papers/39905663 | PubMed |
| 7 | 40069710 | Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial. | BMC Med | 2025 | https://conductscience.org/library/papers/40069710 | PubMed |
| 8 | 40293533 | Cadonilimab, a PD-1/CTLA-4 bispecific antibody in unresectable hepatocellular carcinoma: a real-world study. | Cancer Immunol Immunother | 2025 | https://conductscience.org/library/papers/40293533 | PubMed |
| 9 | 39390972 | The efficacy and safety of a novel PD-1/CTLA-4 bispecific antibody cadonilimab (AK104) in advanced non-small cell lung cancer: A multicenter retrospective observational study. | Thorac Cancer | 2024 | https://conductscience.org/library/papers/39390972 | PubMed |
| 10 | 38330795 | Real-world outcomes of first-line maintenance therapy for recurrent or metastatic cervical cancer: A multi-center retrospective study. | Int Immunopharmacol | 2024 | https://conductscience.org/library/papers/38330795 | PubMed |
| 11 | 40565299 | Bispecific Antibodies in Solid Tumors: Advances and Challenges. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40565299 | PubMed |
| 12 | 40713827 | Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for EGFR-mutant patients with advanced non-small cell lung cancer after failure of EGFR-tyrosine kinase inhibitors: updated results from cohort 5 in the DUBHE-L-201 study. | J Hematol Oncol | 2025 | https://conductscience.org/library/papers/40713827 | PubMed |
| 13 | 38448606 | The present and future of bispecific antibodies for cancer therapy. | Nat Rev Drug Discov | 2024 | https://conductscience.org/library/papers/38448606 | PubMed |
| 14 | 39426385 | Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China. | Lancet | 2024 | https://conductscience.org/library/papers/39426385 | PubMed |
| 15 | 28756902 | Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). | Lancet | 2017 | https://conductscience.org/library/papers/28756902 | PubMed |
| 16 | 34534429 | Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. | N Engl J Med | 2021 | https://conductscience.org/library/papers/34534429 | PubMed |
| 17 | 39492841 | Second-line treatment of PD-1 and CTLA-4 blockade combined with liposomal irinotecan plus leucovorin and fluorouracil for advanced cholangiocarcinoma: study protocol of a single-arm, prospective phase II trial. | Ther Adv Med Oncol | 2024 | https://conductscience.org/library/papers/39492841 | PubMed |
| 18 | 40057343 | Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China. | Lancet | 2025 | https://conductscience.org/library/papers/40057343 | PubMed |
| 19 | 35747125 | Machine Learning of Dose-Volume Histogram Parameters Predicting Overall Survival in Patients with Cervical Cancer Treated with Definitive Radiotherapy. | J Oncol | 2022 | https://conductscience.org/library/papers/35747125 | PubMed |
| 20 | 19720909 | Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. | J Clin Oncol | 2009 | https://conductscience.org/library/papers/19720909 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42022176 | Targeted Therapy and Immunotherapies in Hepatocellular Carcinoma: Mechanisms and Clinical Studies. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42022176 | PubMed |
| 41373687 | Editorial for the Special Issue "Current Research on Cancer Biology and Therapeutics: Third Edition". | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41373687 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CTLA4 | 1493 | PubTator's text mining | https://conductscience.org/library/genes/1493 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41136631
GET https://conductscience.org/api/papers/v1/41136631/references?page=2